A case of catastrophic anti phospholipid syndrome with superimposed aspergillus infection
Catastrophic anti phospholipid syndrome or CAPS for short, is a rare, devastating form of antiphospholipid syndrome that is characterized by successive multiple thrombi and multiorgan failure. One of the complications of antiphospholipid syndrome is nonbacterial thrombotic endocarditis or marantic endocarditis. Due to the nonspecific presentation of multiorgan failure it is difficult to have an early diagnosis. We are presenting a case of catastrophic anti phospholipid syndrome with superimposed aspergillus infection
Shruti Chaturvedi and Keith McRae. Diagnosis and management of the antiphospholipid syndrome. Blood Reviews, 2017-11-01, Volume 31, Issue 6, Pages 406-417, Copyright © 2017 Elsevier Ltd. https://doi.org/10.1016/j.blre.2017.07.006
Elias Mazokopakis, Periklis K. Syros, Ioannis K. Starakis. Nonbacterial Thrombotic Endocarditis (Marantic Endocarditis) in Cancer Patients. Cardiovascular & Hematological Disorders-Drug Targets Volume 10 , Issue 2 , 2010. DOI: 10.2174/187152910791292484
Roldan CA, Sibbitt WL, Qualls CR, Jung RE, et al. Libman-Sacks endocarditis and embolic cerebrovascular disease. JACC Cardiovasc Imaging. 2013 Sep;6(9):973-83. https://www.jacc.org/doi/abs/10.1016/j.jcmg.2013.04.012
Demin AA, Chapaeva NN, Trifonova MA. Affection of cardiovascular system in antiphospholipid syndrome with non-bacterial thrombotic endocarditis. Ter Arkh. 2008;80(8):51-3.
Asherson R.A., Cervera R., de Groot P.G., et al: Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: pp. 530-534. 10.1191/0961203303lu394oa
Gerard ESPINOSA, Ignasi RODRÍGUEZ-PINTÓ, Ricard CERVERA: Catastrophic antiphospholipid syndrome: an update. Panminerva Medica 2017 September;59(3):254-68. DOI: 10.23736/S0031-0808.17.03324-9
Asherson RA, Cervera R. Catastrophic antiphospholipid syndrome. Curr Opin Hematol. 2000;7(5):325–9. 10.1097/00005792-199805000-00005
MarcPineton de Chambruna, Romaric Larcher, FrédéricPèned, et al: CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. Journal of Autoimmunity. Volume 103, September 2019, 102292. https://doi.org/10.1016/j.jaut.2019.06.003
Cervera R, Piette JC, Font J, Khamashta MA, et al: Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019. https://doi.org/10.1002/art.10187
Andreoli L, Chighizola CB, Banzato A, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res (Hoboken). 2013 Nov;65(11):1869-73. https://doi.org/10.1002/acr.22066
Oscar Danilo Ortega Hernandez, Nancy Agmon-Levina, Miri Blank, et al. The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: Compelling evidence. Journal of Autoimmunity Volume 32, Issue 1, February 2009, Pages 1-6.DOI 10.1016/j.jaut.2008.10.003
Yegneswaran Prakash P, Pandit V, Rao SP: Fulminant antiphospholipid antibody syndrome complicated by Aspergillus tracheobronchitis. Medical Mycology Case Reports Volume 1, Issue 1, 2012, Pages 99-102. 10.1016/j.mmcr.2012.10.003
Nayef M. Kazzaz, W. Joseph McCune, and Jason S. Knight: Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016 May; 28(3): 218–227. DOI10.1097/BOR.0000000000000269
Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006;54:2568–2576. https://doi.org/10.1002/art.22018
Berman H, Rodríguez-Pintó I, Cervera R,et al: Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev. 2013 Sep; 12(11):1085-90. DOI 10.1016/j.autrev.2013.05.004
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright policies & self-archiving
We are a RoMEO green journal.
Author's Pre-print: author can archive pre-print (ie pre-refereeing)
Author's Post-print: author can archive post-print (ie final draft post-refereeing)
Publisher's Version/PDF: author can archive publisher's version/PDF
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access and Benefits of Publishing Open Access).
This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.
Articles are published Under License of Creative Commons Attribution 4.0 License © Copyright Policy
Any permissions should be requested to PLSclear.com